The role of Federal legislation on breast cancer disparities
The role of Federal legislation on breast cancer disparities
批准号:
7685244
负责人:
ROBERT A LEVINE
金额:
$21.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-01 至 2013-11-30
关键词:
AccountingAddressAdverse effectsAfrican AmericanAgeAnti-Retroviral AgentsAreaBehavioralBiologicalCaringCenters of Research ExcellenceCessation of lifeCharacteristicsDataDeveloped CountriesDiagnosisDiseaseElderly womanEpidemiologyEthnic OriginFoodHIVHealth InsuranceHealthcareIndividualInterventionLawsLicensingLifeLife ExpectancyLogistic RegressionsMammographyMedicalMedical AssistanceMedicareMedicare claimModelingModificationMorbidity - disease rateNational Cancer InstituteNational Center on Minority Health and Health DisparitiesNaturePatientsPersonsPoliciesPositioning AttributeRaceRelative (related person)Research PersonnelResourcesRespiratory distressRoleSafetyScreening procedureServicesSocioeconomic StatusSolutionsSourceStatutes and LawsTestingTimeTranslatingUnited States Centers for Medicare and Medicaid ServicesUnited States Food and Drug AdministrationWomanbasecancer health disparitycancer information systemdrug markethazardhealth disparityhuman very old age (85+)innovationlow socioeconomic statusmalignant breast neoplasmmortalityolder womenprematureprogramspsychologicsocialsocioeconomicssurfactant
中文摘要
每年,美国用于医疗保健的支出占国内生产总值(gdp)的比例都高于中国
英文摘要
Each year, the US spends a larger percentage of its gross domestic product on health care than
any other nation.1 Yet, rather than achieving a higher standing among industrialized nations for
such key indicators as life expectancy, the US position has declined2. Numerous investigators
assert that this occurs, in part, because the nation's preoccupation with health care diverts
resources from potentially more important targets such as the solution of social, psychological,
behavioral and environmental problems.2"9' ¿'n In the present proposal, we suggest that
difficulties posed by the magnitude and nature of US health care spending go beyond diversion.
We hypothesize that federal laws and policies related to health care inadvertently promote racial
disparities in mortality by favoring the acquisition of life saving innovations by those of higher
socioeconomic status. The resulting premature loss of life may also be contributing to the
declining US position relative to other industrialized nations.
We have shown that Black;white disparities in US mortality increased after three lifesaving,
disease-specific innovations with clear start dates, namely Surfactant for Respiratory Distress
X licensed by the Food and_DmAdininistration FDA in 1 9 8 9 i h . A : t w e
Anti-Retroviral Therapy for Human Immunodeficiency Virus (HIV disease) licensed by the FDA
from December 1995 to March 1996 ; and mammography re-imbursement by Medicare in 1991.
For RDS, mean (+/-standard deviation) 5 year pre- and post-innovation black:white Mortality
Rate Ratios (MRRs) were 1.92 (+/-0.26) and 2.70 (+/-0.37) (p=0.005). The corresponding MRRs
were 3.98 +/-0.51 and 7.98 +/-0.37 (p < 0.001) for HIV mortality (age-adjusted, 25-64 years) and
0.93 +/-0.05 and 1.04 +/-0.04 (p=0.003) for breast cancer (age-adjusted, 65-85+ year old
women).12 Thus, after each innovation, rates declined less in blacks than whites, translating into
as many as 18,995 premature deaths among blacks through 2004. These descriptive data are
compatible with the hypothesis that Medicare law (which defines medical assistance (health
insurance) as a cash benefit regardless of the extent to which cash is a barrier to service
acquisition) and administrative policies of the Food and Drug Administration (basing drug
marketing decisions on biological safety/efficacy without considering possible adverse social
effects) contribute to disparities in black:white mortality, in part, by actively (Medicare) and
passively (Food and Drug Administration) helping to assure that the benefits of life-saving
innovations are more likely to accrue to persons of higher socioeconomic status. This is not to
deny the beneficial effects of these programs, but rather to suggest that any health-related
intervention may have unintended, adverse effects.
The present collaborative study will focus on breast cancer in order to address the overarching
hypotheses as they pertain to Medicare law. We will purchase Medicare claims data from the
Center for Medicare and Medicaid Services (CMS) and SEER-Medicare data. We shall also use
data from the Area Resource File and the National Cancer Institute's Cancer Information System
(CIS) to locate medical resources and programs that support utilization of screening
mammography. We shall then pursue the following aims and hypotheses:
Specific Aim 1: To determine the importance of regional level characteristics on the utilization
of mammography by elderly women in the years 1992 to 1995 and 2002 to 2005. We will use
the Medicare data to identify patient level information (e.g., age, race, co-morbidity, regular
source of care), and both ARF and CIS to identify regional level data. We will use multilevel
logistic regression to model women clustered within regions and states. The hypothesis to be
tested will be:
H-l: Regional and state level characteristics will have a significant effect on mammography
utilization after adjusting for individual factors.
H-2: The effect of regional and state level characteristics on mammography utilization will be
different for African American and White women.
H-3: The region having the greatest equitability for screening mammography utilization will be
more likely to have programs in place aiming to increase mammography utilization and reduce
disparities.
Specific Aim 2: To examine the association between screening mammography utilization and
breast cancer survival of women age 67 and older. For the years 1992 through 2005, we will use
Statistical Epidemiology and End Results (SEER)-Medicare data to take potential confounding
(e.g., age at diagnosis) and effect modification (e.g., race/ethnicity) of this association into
account. Using Cox proportional hazard regression, we will test the following hypotheses:
H-4: Relative to moderately successful or relatively unsuccessful places, highly unsuccessful
places will be more likely to have lower contextual socioeconomic status, low survival from
breast cancer, and greater percentage increase in racial disparity in survival over time.
H-5: Relative to places that are jTighIy_unsuccessful, moderately successful or relatively
unsuccessful with regard to screening mammography utilization, exceptionally successful places
will be more likely to have high survival from breast cancer, and to have greater percentage
reduction in racial disparity in survival over time. Socioeconomic status is not given as a part of
this hypothesis to allow for the possibility that, under present conditions, exceptionally
successful places may be those that overcome contextual socioeconomic barriers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Research Core
-
批准号:8401855
-
项目类别:
-
资助金额:$10.72万
-
财政年份:2012
-
负责人:ROBERT A LEVINE
-
依托单位:
The role of Federal legislation on breast cancer disparities
-
批准号:8374988
-
项目类别:
-
资助金额:$16.53万
-
财政年份:2011
-
负责人:ROBERT A LEVINE
-
依托单位:
Research Core
-
批准号:8374980
-
项目类别:
-
资助金额:$17.73万
-
财政年份:2011
-
负责人:ROBERT A LEVINE
-
依托单位:
Research Core
-
批准号:7685225
-
项目类别:
-
资助金额:$21.2万
-
财政年份:2009
-
负责人:ROBERT A LEVINE
-
依托单位:
Conference on Complementary and Alternative Medicine
-
批准号:7095601
-
项目类别:
-
资助金额:$2.5万
-
财政年份:2005
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:7784799
-
项目类别:
-
资助金额:$46.62万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:8420189
-
项目类别:
-
资助金额:$39.89万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:8197425
-
项目类别:
-
资助金额:$40.98万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:6862312
-
项目类别:
-
资助金额:$7.61万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:7093175
-
项目类别:
-
资助金额:$41.74万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:8041082
-
项目类别:
-
资助金额:$40.61万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:6890950
-
项目类别:
-
资助金额:$48.49万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:6771846
-
项目类别:
-
资助金额:$42.74万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
Effect of Mitral Regurgitation on Ischemic LV Remodeling
-
批准号:6685826
-
项目类别:
-
资助金额:$42.74万
-
财政年份:2003
-
负责人:ROBERT A LEVINE
-
依托单位:
ACTIVE PATCH THERAPY FOR ISCHEMIC MITRAL REGURGITATION
-
批准号:6571618
-
项目类别:
-
资助金额:$21.94万
-
财政年份:2002
-
负责人:ROBERT A LEVINE
-
依托单位:
ACTIVE PATCH THERAPY FOR ISCHEMIC MITRAL REGURGITATION
-
批准号:6665299
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2002
-
负责人:ROBERT A LEVINE
-
依托单位:
ACTIVE PATCH THERAPY FOR ISCHEMIC MITRAL REGURGITATION
-
批准号:6789296
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2002
-
负责人:ROBERT A LEVINE
-
依托单位:
ISCHEMIC MITRAL REGURGITATION:FROM MECHANISMS TO THERAPY
-
批准号:6888162
-
项目类别:
-
资助金额:$13.76万
-
财政年份:2001
-
负责人:ROBERT A LEVINE
-
依托单位:
ISCHEMIC MITRAL REGURGITATION: FROM MECHANISM TO THERAPY
-
批准号:7359612
-
项目类别:
-
资助金额:$18.71万
-
财政年份:2001
-
负责人:ROBERT A LEVINE
-
依托单位:
ISCHEMIC MITRAL REGURGITATION: FROM MECHANISM TO THERAPY
-
批准号:7650398
-
项目类别:
-
资助金额:$18.68万
-
财政年份:2001
-
负责人:ROBERT A LEVINE
-
依托单位:
海外基金